Skip to main content

Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2–3 kidney disease

International Urology and Nephrology volume 46, pages 411–415 (2014)Cite this article

Abstract

Purpose

Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) plays a role in cellular proliferation, migration, and apoptosis. The current study aimed to analyze whether soluble TWEAK levels are associated with the severity of coronary arterial disease (CAD) in CKD patients.

Methods

Ninety-seven patients diagnosed with CKD stages 2–3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique.

Results

Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r 2 = 0.287). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01).

Conclusions

Our results indicate a relationship between sTWEAK levels and CAD in CKD stages 2–3 patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302:1782–1789

    PubMed  Article  Google Scholar 

  2. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD (2002) Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 62:1402–1407

    PubMed  Article  Google Scholar 

  3. Zoccali C (2006) Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 17:S61–S63

    PubMed  Article  Google Scholar 

  4. Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev 7:411–425

    CAS  Google Scholar 

  5. National Kidney Foundation (2004) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1–S202

    Google Scholar 

  6. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM (2009) Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 4:1716–1723

    CAS  PubMed  Article  Google Scholar 

  7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470

    CAS  PubMed  Article  Google Scholar 

  8. Judkins MP (1967) Selective coronary arteriography part I: A percutaneous transfemoral technique. Radiology 89:815–824

    CAS  PubMed  Google Scholar 

  9. Gensini GG (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51:606

    CAS  PubMed  Article  Google Scholar 

  10. Wright J, Hutchison A (2009) Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag 5:713–722

    PubMed Central  PubMed  Google Scholar 

  11. Doganer YC, Aydogan U, Aydogdu A, Aparci M, Akbulut H, Nerkiz P, Turker T, Cayci T, Barcin C, Saglam K (2013) Relationship of cystatin C with coronary artery disease and its severity. Coron Artery Dis 24(2):119–126

    PubMed  Article  Google Scholar 

  12. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel JB, Ortiz A, Meilhac O, Egido J (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27:916–922

    CAS  PubMed  Article  Google Scholar 

  13. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimburger O, Marron B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM (2009) Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 4:110–118

    CAS  PubMed  Article  Google Scholar 

  14. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM (2009) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 29:2061–2068

    CAS  PubMed  Article  Google Scholar 

  15. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, Ortiz A (2006) Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 70:1750–1758

    CAS  PubMed  Article  Google Scholar 

  16. Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Egido J, Ortiz A (2009) Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 13:3329–3342

    PubMed  Article  Google Scholar 

  17. Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM (2006) Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 37:2044–2053

    CAS  PubMed  Article  Google Scholar 

  18. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, Ortega L, Egido J, Blanco-Colio LM (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207:103–110

    CAS  PubMed  Article  Google Scholar 

  19. Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR (2012) Serum levels of TWEAK and scavenger receptor CD163 in type 1 Diabetes mellitus: relationship with cardiovascular risk factors. A Case-Control Study. PLoS ONE 7(8):e43919

    PubMed Central  PubMed  Article  Google Scholar 

  20. Gungor O, Kircelli F, Asci G, Carrero JJ, Tatar E, Demirci MS, Ozbek SS, Ceylan N, Toz H, Ozkahya M, Ok E (2012) Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients? J Nephrol 13:0

    Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interest to declare.

Author information

Affiliations

  1. Department of Nephrology, Ankara Education and Research Hospital, Ankara, Turkey

    Alper Azak, Bülent Huddam, Gülay Koçak, İbrahim Akdağ & Murat Duranay

  2. Department of Internal Medicine, Haydarpaşa Numune Education and Research Hospital, Istanbul, Turkey

    Mehmet Fatih Akdoğan

  3. Department of Nephrology, Haydarpaşa Numune Education and Research Hospital, Istanbul, Turkey

    Nazım Denizli, Murat Gücün, Recep Demirci, Bilal Yılmaz & Mehmet Dikeç

  4. Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Center, Istanbul, Turkey

    Mustafa Adem Tatlısu

  5. Department of Biochemistry, Haydarpaşa Numune Education and Research Hospital, Istanbul, Turkey

    Murat Bakırtaş

Authors
  1. Alper Azak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Fatih Akdoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nazım Denizli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bülent Huddam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gülay Koçak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Murat Gücün
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa Adem Tatlısu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Recep Demirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bilal Yılmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mehmet Dikeç
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Murat Bakırtaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. İbrahim Akdağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Murat Duranay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alper Azak.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Azak, A., Akdoğan, M.F., Denizli, N. et al. Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2–3 kidney disease. Int Urol Nephrol 46, 411–415 (2014). https://doi.org/10.1007/s11255-013-0562-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-013-0562-4

Keywords

  • Chronic kidney disease
  • Coronary arterial disease
  • Gensini score
  • TWEAK